These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34537847)

  • 21. Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines.
    Heo JY; Seo YB; Jeong HW; Choi MJ; Min KH; Choi WS; Lee J; Noh JY; Cheong HJ; Kim WJ; Song JY
    Vaccine; 2020 Nov; 38(49):7747-7755. PubMed ID: 33164798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
    McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
    Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
    Ouldali N; Levy C; Minodier P; Morin L; Biscardi S; Aurel M; Dubos F; Dommergues MA; Mezgueldi E; Levieux K; Madhi F; Hees L; Craiu I; Gras Le Guen C; Launay E; Zenkhri F; Lorrot M; Gillet Y; Béchet S; Hau I; Martinot A; Varon E; Angoulvant F; Cohen R
    JAMA Pediatr; 2019 Apr; 173(4):362-370. PubMed ID: 30715140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.
    Lewnard JA; Bruxvoort KJ; Fischer H; Hong VX; Grant LR; Jódar L; Cané A; Gessner BD; Tartof SY
    Clin Infect Dis; 2022 Sep; 75(5):832-841. PubMed ID: 34967907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
    Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017.
    Kobayashi M; Spiller MW; Wu X; Wang R; Chillarige Y; Wernecke M; MaCurdy TE; Kelman JA; Deng L; Shang N; Whitney CG; Pilishvili T; Lessa FC
    JAMA Intern Med; 2023 Jan; 183(1):40-47. PubMed ID: 36469350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of 13-valent pneumococcal conjugate vaccine on radiological primary end-point pneumonia among cases of severe community acquired pneumonia in children: A prospective multi-site hospital-based test-negative study in Northern India.
    Awasthi S; Kohli N; Agarwal M; Pandey CM; Rastogi T; Pandey AK; Roy C; Mishra K; Verma N; Kumar CB; Jain PK; Yadav R; Dhasmana P; Chauhan A; Mohindra N; Shukla RC
    PLoS One; 2022; 17(12):e0276911. PubMed ID: 36520841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
    Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
    LeBlanc J; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang AL; Gillis HD; Martin I; Demczuk WH; LaFerriere C; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy A; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32188585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
    Rezende RPV; Oliveira-Santos M; Andrade LEC; Klumb EM
    Lupus; 2023 Apr; 32(5):694-703. PubMed ID: 36705619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
    Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
    BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
    Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
    Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
    Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
    Zhang T; Zhang J; Shao X; Feng S; Xu X; Zheng B; Liu C; Dai Z; Jiang Q; Gessner BD; Chen Q; Zhu J; Luan L; Tian J; Zhao G
    Vaccine; 2021 Jul; 39(33):4620-4627. PubMed ID: 34253417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.